Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
最新股票文章
為何麥可·貝瑞（Michael Burry）剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票，清空了他的整個投資組合，只保留一支股票，並對這家公司加碼，而其他投資人則紛紛出逃。
18:37, 22 7月 2025
評級和評論
評級和評論
